Telix is pioneering a new cancer modality
We are passionate about improving the quality of life for people with cancer and rare diseases. And we put our patients at the heart of everything we do.
With over 20 clinical trials underway worldwide across a range of diseases, Telix is at the forefront of theranostic drug development.
Telix clinical trials
Telix is pushing the frontiers of diagnostic and therapeutic nuclear medicine through a number of clinical trials, both company-sponsored and in collaboration with leading cancer centres around the globe.
See below list of Telix trials that are currently active. A full listing of Telix clinical trials which also includes active and completed studies can be found at ClinicalTrials.gov.
Prostate cancer / PSMA
| Name / Study | Study Title | Sponsor | Asset | Disease | Intervention | Phase | Status | Location |
|---|---|---|---|---|---|---|---|---|
| China Registration Study
Study ID: NCT05847348 | 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients | Telix | TLX591-CDx | Prostate Cancer | Imaging | III | Recruiting | China |
| NOBLE Registry NOBLE Registry | The NOBLE Registry is collecting prospective, real-world clinical data on the use of Telix’s SPECT-based investigational imaging product TLX599-CDx (99m Tc-iPSMA) | Telix and Oncidium Foundation | TLX599-CDx | Prostate Cancer | Imaging | NA | Recruiting | Global |
| ProstACT GLOBAL
Study ID: NCT04876651 | 177Lu-DOTA-rosopatamab With Best Standard of Care (SoC) for the Second Line of Treatment for Metastatic Castrate-resistant Prostate Cancer, which Expresses PSMA | Telix | TLX591 | Prostate Cancer | Therapy | III | Recruiting | Global |
| ProstACT TARGET
Study ID: NCT05146973 | External Beam Therapy with Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer. A collaborative study with GenesisCare | Telix | TLX591 | Prostate Cancer | Therapy | II | Recruiting | Australia |
| CUPID
Study ID: NCT04726033 | 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) (CUPID) | Telix | TLX592 | Prostate Cancer | Therapy (2nd Gen) | I | Recruiting | Australia |
Kidney cancer / CAIX
| Name / Study | Study Title | Sponsor | Asset | Disease | Intervention | Phase | Status | Location |
|---|---|---|---|---|---|---|---|---|
| ZIRCON China Study | TLX250-CDx for PET/CT Imaging of ccRCC in Chinese Patients | Telix | TLX250-CDx | Kidney Cancer | Imaging | III | Start-up | China |
| TLX250-CDx US EAP
Study ID: NCT06090331 | TLX250-CDx US Expanded Access Program (EAP) | Telix | TLX250-CDx | Kidney Cancer | Imaging | EAP | Recruiting | US |
| TLX250-CDx EU NPP | TLX250-CDx EU Named Patient Pathway (NPP) | Telix | TLX250-CDx | Kidney Cancer | Imaging | NPP | Recruiting | Netherlands |
| STARLITE-1
Study ID: NCT05663710 | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | MD Anderson Cancer Center | TLX250 | Kidney Cancer | Therapy | II | Recruiting | US |
| STARLITE-2
Study ID: NCT05239533 | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | Memorial Sloan Kettering Cancer Center | TLX250 | Kidney Cancer | Therapy | II | Recruiting | US |
| ZiP-UP
Study ID: NCT05046665 | A Single-centre, Open-label, Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients | South Metropolitan Health Service | TLX250-CDx | Bladder or Urothelial Cancer | Imaging | I | Recruiting | Australia |
| STARBURST
Study ID: NCT05563272 | Exploration of CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors. | Telix | TLX250-CDx | CAIX Expressing Solid Tumors | Imaging | II | Recruiting | US |
| STARSTRUCK
Study ID: NCT05868174 | Evaluation of different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors. | Telix | TLX250 | CAIX Expressing Solid Tumors | Therapy | Ib | Recruiting | Australia |
Glioblastoma / LAT-1
| Name / Study | Study Title | Sponsor | Asset | Disease | Intervention | Phase | Status | Location |
|---|---|---|---|---|---|---|---|---|
| IPAX-2
Study ID: NCT05450744 | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma | Telix | TLX101 | Glioblastoma | Therapy | I/II | Recruiting | Australia, New Zealand |
| IPAX-Linz | TBC | Kepler University Hospital | TLX101 | Glioblastoma | Therapy | II | Recruiting | Austria |
Sarcoma / PDGFRα
| Name / Study | Study Title | Sponsor | Asset | Disease | Intervention | Phase | Status | Location |
|---|---|---|---|---|---|---|---|---|
| TLX300-CDx in STS | Phase I Study of 89Zr-labelled olaratumab in Soft Tissue Sarcoma (STS) | Telix | TLX300-CDx | STS | Imaging | I | Start-up | Australia |
Bone marrow conditioning / CD66
| Name / Study | Study Title | Sponsor | Asset | Disease | Intervention | Phase | Status | Location |
|---|---|---|---|---|---|---|---|---|
| TLX66 in AML | Phase II Study of 90Y-labelled Anti-CD66 antibody in Acute Myeloid Leukaemia (AML) | Telix | TLX66 | AML | Therapy | II | In planning | Australia |
| GOSH
Study ID: NCT04856215 | Open Label, Phase II Study of 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia | Great Ormond Street Hospital | TLX66 | Pediatric Leukemia | Therapy | II | Recruiting | UK |
Compassionate use
Telix is often contacted to provide access to our products under compassionate use. We respect the treatment journey of the patient and the independence of healthcare professionals in making their treatment decisions. Telix tries to accommodate such requests whenever it is clinically, ethically and practically feasible to do so.
You can find Telix’s compassionate use policy here: